Agent for treatment of keratoconjunctive disorder

A therapeutic agent and corneal technology, applied in sensory diseases, organic active ingredients, organic chemistry, etc., can solve problems such as reports of pharmacological effects that have not yet been studied, and achieve the effect of improving the effect

Inactive Publication Date: 2007-08-08
SANTEN PHARMA CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, there is no report on the pharmacological effects of the above-mentioned carboxylic acid compounds on eye diseases such as keratoconjunctivopathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for treatment of keratoconjunctive disorder
  • Agent for treatment of keratoconjunctive disorder

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] The results of pharmacological tests and preparation examples are given below. The above examples are used to further understand the present invention, and the scope of the present invention is not limited thereto.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

A new medicinal use of E-4-[4-(5-methyl-2phenyl-4-oxazolylmethoxy)benzyloxyimino]-4-phenylbutyric acid, Z-2-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyimino]-2-(4-phenoxyphenyl)acetic acid, 2-[2-propyl-3[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic acid, 2(S)-methoxy-3-[4-[3-(4phenoxyphenoxy)propoxy]phenyl]propionic acid, or a salt of any of these. These carboxylic acid compounds and salts thereof each produces an excellent alleviating effect on corneal disorder models and is useful as a therapeutic agent for keratoconjunctiva disorders such as dry eye, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, subepithelial corneal defects, subepithelial conjunctival defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, and filamentary keratitis.

Description

technical field [0001] The present invention relates to dry eye, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defect, conjunctival epithelial defect, keratoconjunctivitis sicca, and superior keratoconjunctivitis (superior limbickeratoconjunctivitis), filamentous keratitis (Filamentary Keratitis) and other keratoconjunctivitis therapeutic agents, the therapeutic agent contains (1) E-4-[4-(5-methyl-2-phenyl-4-oxo Azolylmethoxy)benzyloxyimino]-4-phenylbutanoic acid, (2)Z-2-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy) Benzyloxyimino]-2-(4-phenoxyphenyl)acetic acid, (3)2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl) )-5-hydroxyphenoxy]propoxy]phenoxy]benzoic acid, (4)2(S)-methoxy-3-[4-[3-(4-phenoxyphenoxy) Propoxy] phenyl] propionic acid and at least one of the salts of the above compounds as an active ingredient. Background technique [0002] The cornea is a transparent, avascular tissue with a diameter of about 1 cm and a thickness ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/192A61K31/421A61K31/603A61P27/02A61P43/00C07D263/32
CPCA61K31/603A61K31/421A61K31/192A61K9/0048A61P27/02A61P43/00
Inventor 中村雅胤平井慎一郎柴垣圭一
Owner SANTEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap